Prostate Cancer
Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent.
September 11, 2024
A new silicon phthalocyanine dye induces pyroptosis in prostate cancer cells during photoimmunotherapy.
September 10, 2024
Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patients.
September 10, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial.
September 10, 2024
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.
September 10, 2024
Predictive factors of hemoglobin drop after robot-assisted radical prostatectomy: a single center prospective study.
September 10, 2024
Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer.
September 9, 2024
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
September 9, 2024
Development of prediction models based on risk scores for clinically significant prostate cancer on MRI/TRUS fusion biopsy.
September 6, 2024
PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers.
September 6, 2024
The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate.
September 6, 2024
Comparison of Pathologist and Artificial Intelligence-based Grading for Prediction of Metastatic Outcomes After Radical Prostatectomy.
September 6, 2024
The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions.
September 5, 2024
A Multi-Institutional Study of MR/US Fusion Guided Nanoparticle Directed Focal Therapy for Prostate Ablation.
September 5, 2024
Talazoparib for the treatment of prostate cancer.
September 5, 2024